Polyclonal immunoglobulin E antibodies specific to timothy grass allergens (Timothy grass-specific IgE)

Polyclonal immunoglobulin E (IgE) antibodies specific to timothy grass (Phleum pratense) allergens are the primary mediators of seasonal allergic reactions in sensitized individuals (PubMed: 18211313). These antibodies are produced by plasma cells following exposure to timothy grass pollen, which contains potent allergens such as Phl p 1 and Phl p 5 (UniProt: P13447). The IgE molecules circulate in the blood and bind to high-affinity FcεRI receptors on the surface of mast cells and basophils (NIH: NBK538261). Upon subsequent exposure to timothy grass pollen, the allergens cross-link the surface-bound IgE, triggering the immediate release of inflammatory mediators like histamine, prostaglandins, and leukotrienes. This process results in the clinical manifestations of hay fever, including sneezing, rhinorrhea, and potentially exacerbating allergic asthma (PubMed: 10446082). Therapeutic interventions focus on either neutralizing these antibodies using anti-IgE biologics like Omalizumab or modifying the immune response through allergen-specific immunotherapy (AIT) to reduce IgE production and increase protective IgG4 levels (DrugBank: DB00043). Monitoring the levels and affinity of these specific IgE antibodies is essential for diagnosing grass pollen allergy and assessing the efficacy of desensitization treatments.

Other names

Phleum pratense-specific IgETimothy grass pollen-specific IgEAnti-Phl p IgEsIgE to timothy grassTimothy grass-specific sIgE

Neutralization of circulating IgE to prevent binding to high-affinity FcεRI receptors on mast cells and basophils; induction of immune tolerance and protective IgG4 antibody production through allergen-specific immunotherapy (AIT).